HCG

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone that mimics luteinizing hormone to stimulate testosterone production and support fertility, with a clinical history anchored in treating infertility. Users typically run protocols ranging from 200 µg to 6.3 mg, with 300 µg being the most common dose, often administered on a weekly basis, while clinician-tier guidance suggests 250 µg daily. Readers should note that the off-label evidence base for HCG is significantly thinner than the broader discourse suggests, as most exploratory indications lack posted results. While injection-site reactions occasionally surface, side effects are not a consistent theme in community reports.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.54.72.83.72.91.0

Research Evidence

Evidence shape

HCG carries a high evidence tier, supported by extensive clinical research primarily focused on infertility and reproductive medicine. With 130 registered trials and 50 distinct sponsors, the literature includes Phase 3 studies and blinded results that establish a clear clinical profile for its primary indications. However, the breadth of research is heavily skewed; while eight indications have published results, the vast majority of the 71 mapped conditions remain exploratory or rely on single-trial data, signaling that HCG’s clinical utility is concentrated in specific reproductive applications rather than broad therapeutic use.

Depthhow much
138 registered trials
82 completed · 23 with posted results · 12 recruiting / active · combined n=3527
Breadthhow many areas
71 indications mapped
10 with results · 55 thin / exploratory · 1 animal-only · 52 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
7 blinded with results · 52 distinct sponsors · AE rows aggregated from 8 trials · 35 linked publications on registered trials
Breadth and depth147 rows captured
Human
direct clinical signal
138
Animal
translational support
3
In vitro
mechanistic support
6
HighMediumLow

Anecdotal efficacy

HCG side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Eternal PEP
--
20 mg
$75.00
$3.75/mg
2
Axiom Labs UK
GB
10 mg
$53.69
$5.37/mg
3
Trulabpeptides
US
10 mg
$58.00
$5.8/mg
4
Vistara Labs
CA
10 mg
$68.00
$6.8/mg
5
Game Changer Peptides
--
10 mg
$95.00
$9.5/mg
6
dubai.direct-peptides.com
AE
2 mg
$47.37
$23.68/mg

price offers can be sorted by column

1-6 of 7

HCG dosing & protocol

How HCG is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 82
Typical dose
250 µg200 µg – 250 µg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 17 reported doses · darker = more
Frequency
daily
Route
subQ

Across the research trials (n=82), HCG was administered subcutaneously at a typical dose of 250 mcg daily, with individual doses ranging from 200 to 250 mcg.

82 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
250 µg
typical
0
2 mg
4 mg
6 mg
8 mg
across 1 dosed source · darker = more agree
By reported cadence
Daily250 µg · n=1
Frequency
daily
Route
subQ

Based on a single source, the clinician practice tier reports a subcutaneous dose of 250 micrograms taken daily, with no reported cycling or weight‑based adjustment.

1 source
Anecdotal
Community-reported real-world use · n = 6
Typical dose
300 µg200 µg – 6.3 mg
typical
0
2 mg
4 mg
6 mg
8 mg
distribution of 6 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly weekly
Route
subQ

Most community users report a weekly dose of around 300 mcg (range 250‑500 mcg), while smaller groups dose daily at about 6.3 mg, three times per week at roughly 200 mcg, or follow an unscheduled pattern around 1 mg.

6 sources

Regulatory safety notes

Warnings and precautions
  • • WARNINGS: HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions and adverse reactions d…
  • • The principal serious adverse reactions are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain and/or pleural effusion, (2) Rupture of ovarian cysts with resultant hemoperitoneum, (3) Multiple births and (4)…
Contraindications
  • • CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG.

Related peptides

PT-141Kisspeptin-10TriptorelinOxytocinGonadorelin